Skip to content

Study · In vitro (cells) · 1993

3 results

Regulation and biological effect of endogenous insulin-like growth factor binding protein-5 in human osteoblastic cells.

Conover CA, Kiefer MC

The Journal of clinical endocrinology and metabolism1 May 1993Cited by 86 (Europe PMC)

PMID7684391 (opens in a new tab)DOI10.1210/jcem.76.5.7684391 (opens in a new tab)PepBankPUB-07684391
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In U-2 cells, des(1‑3)IGF-I failed to increase medium IGFBP-5 levels.

    In plain wordsIn cells, des(1‑3)IGF-I did not increase IGFBP-5 in the culture medium.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeMedium IGFBP-5 accumulation
    Study

    humann: not reported in source

    U-2 osteosarcoma cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    On the other hand, des(1-3)IGF-I and [QAYL]IGF-I, IGF-I analogs that did not bind IGFBP-5, failed to elicit an increase in medium IGFBP-5.

Studies that did not test the peptide alone2

In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  1. 02LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cells)Mechanism

    In U-2 cells, endogenous IGFBP-5 did not inhibit des(1‑3)IGF-I-stimulated proliferation.

    In plain wordsIn cells, natural IGFBP-5 did not inhibit proliferation stimulated by des(1‑3)IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeIGFBP-5 inhibition of stimulated proliferation
    Study

    humann: not reported in source

    U-2 osteosarcoma cells
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    Endogenous IGFBP-5 inhibited IGF-I but not des(1-3)IGF-I-stimulated U-2 cell proliferation.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

  2. 03LabNot a test of IGF-1 DES (des(1-3)IGF-I) aloneIn vitro (cell-free)Mechanism

    In binding tests, des(1‑3)IGF-I did not bind IGFBP-5.

    In plain wordsIn lab tests, des(1‑3)IGF-I did not bind IGFBP-5.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    No significant changeIGFBP-5 binding
    Study

    humann: not reported in source

    IGFBP-5 binding assay
    Outcome group
    Receptor activity and mechanism · Musculoskeletal

    Source sentences

    Summary
    On the other hand, des(1-3)IGF-I and [QAYL]IGF-I, IGF-I analogs that did not bind IGFBP-5, failed to elicit an increase in medium IGFBP-5.

    In this study, IGF-1 DES (des(1-3)IGF-I) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 DES (des(1-3)IGF-I).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.